New York-based biopharmaceutical company TG Therapeutics Inc. appointed Adam Waldman as chief commercial officer.
Waldman most recently served as the head of U.S. hematology-oncology marketing at Celgene Corp.
Waldman will help with the launch of TG Therapeutics' products over the next few years. The company is developing two therapies targeting hematological malignancies and autoimmune diseases: ublituximab, or TG-1101, and umbralisib, or TGR-1202.
